Osteonecrosis of the maxillary bones caused by bisphosphonates
Keywords:
osteonecrosis of the jaws, bisphosphonate osteonecrosis, bisphosphonateAbstract
Introduction: bisphosphonates are drugs used to treat metabolic bone diseases or malignant hypercalcemia. They are also strong inhibitors of osteoclasts, causing a great decrease in bone resorption. Objectives: describe the dental interest in osteonecrosis of the maxillary bones caused by bisphosphonates. Method: a systematic review was carried out during the period 2018-2022 using the Prisma procedure, the information from research carried out and published was analyzed; Twenty original articles were considered that are related to the topic of maxillary osteonecrosis caused by bisphosphonates, which were obtained from the electronic search of the following databases: PudMed, Scopus and SciELO. Results: bisphosphonates are described as strong inhibitors of osteoclasts, causing a great decrease in bone resorption. Recent research has focused on the search for the association between the alterations caused by the use of bisphosphonates in the soft tissue of the oral cavity and its relevance in the etiopathogenesis of osteonecrosis of the jaws. Conclusions: drug-induced osteonecrosis of the jaw (MRONJ) is necrosis of the jaw bones and a side effect of long-term use of certain drugs such as bisphosphonates or denosumab, antiresorptive medications.
Downloads
References
Villarroel M, Romero M, Orlando R, Pereira V, Molina B. Estudio de apoptosis y adhesión intercelular en mucosa oral de pacientes con osteonecrosis inducida por bifosfonatos. Reumatología Clínica. JOUR. 2019; 15(5): 75-7. doi: 10.1016/j.reuma.2017.10.002.
Bonachea R, Katz J. Medication-related osteonecrosis of the jaw: A multifaceted diagnostic challenge. Mini review. Am J Dent. 2022 Apr;35(2):109-112.
Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O, Peter JU. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD012432. doi: 10.1002/14651858.CD012432.pub3.
Kün-Darbois JD, Fauvel F. Medication-related osteonecrosis and osteoradionecrosis of the jaws: Update and current management. Morphologie. 2021 Jun;105(349):170-187. doi: 10.1016/j.morpho.2020.11.008.
Altay MA DDS, PhD, Radu A DMD, Pack SE DDS, MD, Yıldırımyan N DDS, Flores-Hidalgo A DDS, Baur DA DDS, MD, Quereshy FA MD, DDS, FACS. Medication-related osteonecrosis of the jaw: An institution's experience. Cranio. 2020 Sep;38(5):333-341. doi: 10.1080/08869634.2018.1528711.
Szentpéteri S, Restár L, Németh Z, Vaszilkó M. A gyógyszer okozta állcsontnekrózis prognózisát befolyásoló faktorok [Prognostic factors of the medication-related osteonecrosis of the jaw]. Orv Hetil. 2020 Feb;161(8):283-289. Hungarian. doi: 10.1556/650.2019.31621.
Abed HH, Al-Sahafi EN. The role of dental care providers in the management of patients prescribed bisphosphonates: brief clinical guidance. Gen Dent. 2018 May-Jun;66(3):18-24.
Sánchez López JD, Cariati P, Perez de Perveval Tara MA. Bilateral pathologic mandibular fracture in maxillary osteonecrosis induced by bisphosphonates. Reumatol Clin (Engl Ed). 2020 Jan-Feb;16(1):62-63. English, Spanish. doi: 10.1016/j.reuma.2018.01.005.
Nieckula P, Stempniewicz A, Tubaja M. Prophylaxis of osteonecrosis in the case of patients treated with bisphosphonates: A review paper. Dent Med Probl. 2018 Oct-Dec;55(4):425-429. doi: 10.17219/dmp/99021.
Kitajima S, Mizuno S, Kogiso R, Tsuji C. Severe Maxillary Medication-related Osteonecrosis of the Jaw. Intern Med. 2018 Nov 15;57(22):3341. doi: 10.2169/internalmedicine.0643-17.
Leonardi N, Gilligan G, Piemonte E, Panico R. Alternativas terapéuticas de osteonecrosis maxilar asociada a medicamentos (ONMAM): reportes de dos casos clínicos y revisión de la literatura [Therapeutic alternatives for drug-associated maxillary osteonecrosis (MRONJ): reports of two clinical cases and review of the literature]. Rev Fac Cien Med Univ Nac Cordoba. 2022 Dec 21;79(4):379-382. Spanish. doi: 10.31053/1853.0605.v79.n4.37289.
Santos M, Silveira K, Souza N, Costa D, Inaoka S. Extensive osteonecrosis of the maxilla caused by bisphosphonates: Report of a rare case. J Clin Exp Dent. 2019 Feb 1;11(2):e203-e207. doi: 10.4317/jced.55151.
Zhang J, Park J, Lee JW, Kwon YD, Kim EC. Bisphosphonates hinder osteoblastic/osteoclastic differentiation in the maxillary sinus mucosa-derived stem cells. Clin Oral Investig. 2018 Jun;22(5):1933-1943. doi: 10.1007/s00784-017-2291-z.
Junquera S, Álvarez-Yagüe E, Junquera L, Ugalde R, Rúa L. Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously? J Stomatol Oral Maxillofac Surg. 2020 Nov;121(5):523-526. doi: 10.1016/j.jormas.2019.12.002.
Lungu AE, Lazar MA, Tonea A, Rotaru H, Roman RC, Badea ME. Observational study of the bisphosphonate-related osteonecrosis of jaws. Clujul Med. 2018;91(2):209-215. doi: 10.15386/cjmed-838.
Paulo S, Laranjo M, Paula A, Abrantes AM, Martins J, Marto CM, Coelho A, Casalta-Lopes J, Carvalho L, Carrilho E, Serra A, Botelho MF, Marques Ferreira M. Calcium Phosphate Ceramics Can Prevent Bisphosphonate-Related Osteonecrosis of the Jaw. Materials (Basel). 2020 Apr 22;13(8):1955. doi: 10.3390/ma13081955.
Friedrich RE, Scheuer HA, Höltje W. The effect of bisphosphonate medication on orthodontics and orthognathic surgery in patients with osteogenesis imperfecta. GMS Interdiscip Plast Reconstr Surg DGPW. 2019 Mar 29;8: Doc06. doi: 10.3205/iprs000132.
Duininck JM, de Lange J, Rozema FR, Dubois L. Verlies van de bovenkaak door denosumab [Maxillary osteonecrosis after denosumab treatment]. Ned Tijdschr Tandheelkd. 2018 Dec;125(12):653-657. Dutch. doi: 10.5177/ntvt.2018.12.18143.
Palla B, Burian E, Deek A, Scott C, Anderson J, Callahan N, Carlson ER. Comparing the Surgical Response of Bisphosphonate-Related Versus Denosumab-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg. 2021 May;79(5):1045-1052. doi: 10.1016/j.joms.2020.11.017.
Maeda T, Yamamoto Y, Satoh A, Hayashi T. Refinements in the reconstruction of bisphosphonate-related osteonecrosis of the jaw. JPRAS Open. 2022 Dec 1; 35:1-5. doi: 10.1016/j.jpra.2022.11.004.
Published
How to Cite
Issue
Section
ARK
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Gaceta Médica Estudiantil magazine provides immediate Open Access to its content. It is published under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC) license, which allows sharing (copying and redistributing the material in any medium or format) and adapting (remixing, transforming, and building upon the material), under the terms of acknowledge authorship and not make commercial use of the materials.
